Neurological disease assay kit VEUPLEX™ TBI

biomarqueursclinicalserum

TBI (Traumatic Brain Injury) is, as a common incident worldwide, an injury to the brain caused by an external force and is classified as mild, moderate, and severe. As of 2019, 69 million people worldwide suffer from TBI each year. About 8 million people suffer from TBI in Africa, 5.7 million in Latin America, 4.6 million in North America (US, Canada), 9.2 million in Europe, and 18 million in Southeast Asia. Among TBIs, mild TBI (mTBI-mild TBI) is called "concussion" and accounts for 80% of all traumatic brain injuries. TBI is mostly diagnosed by CT scan or MRI, but in the case of mTBI, less than 10% are normally detected, while the remaining 90% of mTBI patients are not properly treated because it is impossible to diagnose. mTBI, if left neglected, can progress to severe TBI and cause severe after-effects, depending on the patients. Therefore, an accurate diagnosis of mTBI is necessary. In general, mTBI-suspected patients go to small or mid-sized hospitals that cannot be equipped with equipment and manpower for TBI diagnosis, so their samples are sent to clinical laboratories, which take 3~4 days to produce final diagnostic results, disabling fast and effective treatment for mTBI. VEUPLEX™ TBI Assayis a remarkable solution for TBI test results in terms of cost(less than a half), convenience, speed(check results within 50 min.) and accuracy(95% accuracy) compared to previous examinations. Consequently, the only effective TBI diagnostic method in existence is the VEUPLEX™ TBI assay. Features High accuracy Dynamic range > 3 log LOD : ~10 pg/ml Quantitative detection with various magnetic particle lengths